Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label dose-escalation and dose-expansion study of rilvegostomig (AZD2936) in advanced or metastatic non-small cell lung cancer
CTR20222228Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Nov 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rilvegostomig in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Nov 2022; status: active.
02
Drugs
rilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222228.